ARTICLE | Company News
Baxter, Chemo-Sero-Therapeutic Research Institute deal
October 22, 2007 7:00 AM UTC
The institute granted BAX an exclusive license to develop and commercialize recombinant ADAMTS13 worldwide, except in Japan, where the partners will co-commercialize the compound. The disintegrin and...